Due to a lack of robust evidence, the benefits and risks of adding chemotherapy directly into the abdominal cavity (intraperitoneal chemotherapy, or IPC) for stomach cancer are unclear.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback